Milestone Pharmaceuticals Inc. (MIST) is a commercial-stage biopharmaceutical company focused on cardiovascular medicines. Its lead product, CARDAMYST (etripamil) nasal spray, was approved by the U.S. FDA (Food and Drug Administration) in December 2025 as the first self-administered therapy for acute episodes of paroxysmal supraventricular tachycardia (PSVT) in adults.
Across six recent, individually attributed analyst targets, the range runs from $3.00 to $8.00. H.C. Wainwright and TD Cowen sit at the top end at $8.00, Wells Fargo and Piper Sandler at $7.00, Raymond James at $5.00 (lowered from $6.00 in October 2026), and Cantor Fitzgerald at $3.00. The arithmetic mean is about $6.33, rounded to a central target of $6.30.
The dispersion reflects a genuine debate. Bulls emphasize a substantially larger second opportunity in atrial fibrillation with rapid ventricular response (AFib-RVR), citing potential CARDAMYST peak sales of $250 million to $300 million. More cautious analysts, including Raymond James, highlight the need for stronger payer coverage, better gross-to-net trends, and reduced reliance on copay support. Third-party aggregates report average targets from roughly $5.60 to $6.40 depending on the analyst set and timing, underscoring how sensitive the figure is to which targets are included. No single target should be treated as a guarantee.
MIST recently closed near $0.69, near the low end of a 52-week range of approximately $0.63 to $3.06, and far below its post-approval highs. Reaching the $6.30 central target would require upside of about 813%, a very large move by any standard.
The path would depend almost entirely on execution. Milestone is early in a commercial launch: roughly 600 prescriptions were written through April 2026, with steady month-over-month growth, and the company reported $0.56 million of product revenue in the second quarter of 2026. With a market capitalization near $100 million and a runway into the second half of 2027, the valuation today embeds considerable skepticism about whether a niche, self-administered cardiac therapy can scale into a self-sustaining business.
The stock trades near its 52-week low of roughly $0.63, which stands as a key support level. A psychological and technical resistance zone sits near $1.00, with the 52-week high near $3.06 marking a far more distant overhead level. The long-term trend remains firmly negative after a decline of more than 60% over the past year, meaning the stock would need to first stabilize above its lows and then reclaim higher resistance before any move toward the target becomes a realistic technical scenario.
Analyst price targets generally reflect a research horizon of about 12 months, though individual firms differ. Investors should monitor quarterly prescription and revenue figures, payer-coverage announcements, the pace of cash burn, first patient enrollment in the ReVeRA-301 AFib-RVR trial, and the EMA decision expected in the first half of 2027. The next quarterly earnings report, expected in November 2026, will provide an important update on launch conversion and spending.
For traders seeking a more systematic view, Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on shifting market conditions, technical behavior, and AI-driven analysis. The service is designed to help traders discover opportunities, keep track of positions, and spot changing trends more efficiently than manual screening alone. Exploring these AI-generated signals can add a disciplined, data-driven layer to your own research process.
The $6.30 central target for MIST is the average of six current analyst targets spanning $3.00 to $8.00, implying a roughly 813% advance from a price near $0.69. The bull case rests on a successful CARDAMYST launch and the larger AFib-RVR opportunity, while the bear case centers on mounting losses, royalty financing, and reimbursement and clinical uncertainty. The wide target range shows analysts themselves disagree considerably about how this plays out. Reaching the target is possible in theory but would require a sustained, successful commercial ramp — a prospect that remains far from guaranteed. Investors should watch prescription trends, payer coverage, and clinical milestones before drawing any conclusions.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, MIST has been loosely correlated with RCUS. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if MIST jumps, then RCUS could also see price increases.
| Ticker / NAME | Correlation To MIST | 1D Price Change % | ||
|---|---|---|---|---|
| MIST | 100% | -20.63% | ||
| RCUS - MIST | 45% Loosely correlated | -1.91% | ||
| VIR - MIST | 41% Loosely correlated | -17.82% | ||
| TSHA - MIST | 41% Loosely correlated | -2.61% | ||
| RCKT - MIST | 41% Loosely correlated | -3.77% | ||
| NAMS - MIST | 40% Loosely correlated | +0.85% | ||
More | ||||